Business Wire5d
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Pres…
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
Hosted on MSN6d
Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib
That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...